Bartlomiej Kwiek

Warsaw, MZ, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Efficacy and Safety of the PD-1 Agonist JNJ-67484703 in Participants with Atopic Dermatitis: Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial Results.

Efficacy and Safety of the PD-1 Agonist JNJ-67484703 in Participants with Atopic Dermatitis: Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial Results.

Journal: Dermatology and therapy

Published: January 14, 2026

In search for optimal schedule during long term treatment of port wine birthmarks - data from single center retrospective cohort study with a small prospective extension.

In search for optimal schedule during long term treatment of port wine birthmarks - data from single center retrospective cohort study with a small prospective extension.

Journal: Lasers in medical science

Published: December 31, 2025

Improvement of Chronic Spontaneous Urticaria After Glucagon-Like Peptide 1 Receptor Agonist Therapy: Report of Two Cases.

Improvement of Chronic Spontaneous Urticaria After Glucagon-Like Peptide 1 Receptor Agonist Therapy: Report of Two Cases.

Journal: Dermatology and therapy

Published: October 24, 2025

Cendakimab in Patients With Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.

Cendakimab in Patients With Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.

Journal: JAMA dermatology

Published: July 17, 2024

Exploring shared clinical features and successful therapeutic interventions in CARD14-associated papulosquamous eruption.

Exploring shared clinical features and successful therapeutic interventions in CARD14-associated papulosquamous eruption.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: June 25, 2024

Case report: Successful treatment with biologics in a pediatric patient with a severe inflammatory skin disease and novel CARD14 mutation.

Case report: Successful treatment with biologics in a pediatric patient with a severe inflammatory skin disease and novel CARD14 mutation.

Journal: Frontiers in medicine

Published: December 22, 2023

Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study.

Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: September 26, 2023

The Assessment of Activity of Antiseptic Agents against Biofilm of Staphylococcus aureus Measured with the Use of Processed Microscopic Images.

The Assessment of Activity of Antiseptic Agents against Biofilm of Staphylococcus aureus Measured with the Use of Processed Microscopic Images.

Journal: International journal of molecular sciences

Published: October 21, 2022

The In Vitro Ability of Klebsiella pneumoniae to Form Biofilm and the Potential of Various Compounds to Eradicate It from Urinary Catheters.

The In Vitro Ability of Klebsiella pneumoniae to Form Biofilm and the Potential of Various Compounds to Eradicate It from Urinary Catheters.

Journal: Pathogens (Basel, Switzerland)

Published: November 03, 2021

Bullous diseases caused by KRT1 gene mutations: from epidermolytic hyperkeratosis to a novel variant of epidermolysis bullosa simplex.

Bullous diseases caused by KRT1 gene mutations: from epidermolytic hyperkeratosis to a novel variant of epidermolysis bullosa simplex.

Journal: Postepy dermatologii i alergologii

Published: June 26, 2020

Infiltration and Clustering of Major Histocompatibility Complex II+ Antigen-Presenting Cells in the Skin of Patients with Atopic Dermatitis.

Infiltration and Clustering of Major Histocompatibility Complex II+ Antigen-Presenting Cells in the Skin of Patients with Atopic Dermatitis.

Journal: The Journal of investigative dermatology

Published: February 03, 2020

Facial Hypertrophic Port-Wine Stain Treatment Combining Large Spot 532 nm Laser, High-Intensity Focused Ultrasound and Traction Threads.

Facial Hypertrophic Port-Wine Stain Treatment Combining Large Spot 532 nm Laser, High-Intensity Focused Ultrasound and Traction Threads.

Journal: Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]

Published: March 27, 2019

Showing 1-12 of 25

Last Updated: 09/26/2026